InfuCare, a One Equity-backed infusion provider, is exploring a sale through JPMorgan, three sources familiar with the situation tell Axios Pro. The process comes as President Trump’s “most favored nation” drug pricing plan casts a chill over the red-hot infusion market. InfuCare is generating around $50 million of EBITDA, the sources say. The company is angling for up to 20x EBITDA in a sale, two sources say.
Read the full article: InfuCare Working with JPMorgan on Sale //
Source: https://www.axios.com/pro/health-tech-deals/2025/06/03/infucare-one-equity-jpmorgan-sale